About this trial
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant period to optimize patient outcomes. The proposed randomized clinical trial will examine the implementation and effects of integrated, person- and computer-delivered alcohol treatment compared to standard care on alcohol use (assessed by self-report and biomarker), mood, quality of life and survival following AH-LT. Predictors of 12-month post-transplant alcohol outcomes will be explored to allow future improved tailoring and targeting of these treatments.
Eligibility criteria
Qualifiers
English speaking
Disqualifiers
too medically/psychiatrically ill to participate
not able to provide informed consent due to cognitive impairment
Trial design
Treatments tested in this trial
- Integrated AUD Treatment
Treatment groups
Sponsors and collaborators
Johns Hopkins University
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator